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the manifestations of different forms of
leprosy through their functional roles in
antigen presentation and inhibition of
T-cell responses.
Although predisposing major histo-
compatibility complex alleles may
exhibit inefficient antigen presentation,
the LYP-Trp620 allele may have a
pathogenic role in the hyporesponsive-
ness of T cells owing to anomalies in
early T-cell signaling, resulting in
clinical manifestations of leprosy. Con-
trary to our expectations, a significantly
higher number of tuberculoid patients
had PTPN22 1858CT, suggesting that
there may be early T-cell defects in
these patients. This results in a com-
promised immune response to the
infectious agent, which manifests in
the milder form of the disease. Most
healthy people exposed to M. leprae
are resistant to the infection, and with
an effective immune response they do
not develop the disease (Bongiorno
et al., 2008). Because the CT genotype
accounts for only 15–16% of leproma-
tous and tuberculoid patients, other
genes involved in the downregulation
of T-cell responses, such as CTLA-4
and Foxp3, should be investigated for
additional host factors that may be
detrimental in conferring anergy to
M. leprae antigens in lepromatous
leprosy patients.
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TO THE EDITOR
Recent studies have suggested epider-
mal transglutaminase (eTG) as the
autoantigen of dermatitis herpetiformis
(DH) (Sardy et al., 2002) (Donaldson
et al., 2007), but the patient cohorts in
published studies on its clinical utility
in DH have been small. IgA anti-eTG is
present in about 50% of adult celiac
disease (CD) (Hull et al., 2008); how-
ever, its prevalence in a large cohort of
pediatric CD has not been reported.
The primary objective of this study was
to confirm and expand on our pre-
viously published data, and to deter-
mine the clinical utility of IgA anti-eTG
in a large cohort of DH patients. Our
second objective was to further evalu-
ate the relative prevalence of IgA anti-
eTG in a larger cohort of pediatric CD
patients.
Abbreviations: Ab, antibody; CD, celiac disease; DH, dermatitis herpetiformis; eTG, epidermal
transglutaminase; tTG, tissue transglutaminase
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Serum from the following cohorts
was assessed for IgA antibodies (Abs)
against eTG and for traditional markers
associated with gluten-sensitive entero-
pathy (that is, tissue transglutaminase
(tTG) and deamidated gliadin peptides,
IgA and IgG) for comparison: 80 retro-
spective adult DH patients drawn dur-
ing their initial clinical evaluation (all
on a normal diet), 50 prospective adult
DH patients drawn post-diagnosis (7 on
a normal diet and 43 on some level of
gluten restriction), 54 pediatric CD
patients drawn during their initial clin-
ical evaluation (all on a normal diet;
26 males, 1.2–17.9 years, mean¼7.7
years; 28 females, 1.3–18.6 years,
mean¼ 8.5 years), and 49 adult and
77 pediatric normal controls. DH was
diagnosed by characteristic granular
IgA staining of the dermis of perile-
sional skin by direct immunofluores-
cence, and CD was diagnosed by
positive duodenal biopsy and/or posi-
tive serology. All CD patients with
negative biopsy were positive by serol-
ogy (IgA anti-endomysial Ab and anti-
tTG). There were no DH patients with
IgA deficiency (o7 mg per 100 ml).
Two of the pediatric CD patients had
partial IgA deficiency (7–68 mg per
100 ml).
Serum IgA Ab against eTG (human
recombinant) was measured semi-
quantitatively by enzyme immunoassay
as per the manufacturer’s (Immundiag-
nostik Bensheim, Germany) product
insert. As this assay has not yet been
approved in the United States for
in vitro diagnostic use in DH, a cutoff
value of 12 Units (þ 5 SD above the
mean) was established for this study on
the basis of the IgA anti-eTG values
in our normal controls. Serum IgA
and IgG Abs against tTG (human red
blood cells) and deamidated gliadin
peptides (synthetic) were measured
semi-quantitatively by enzyme immu-
noassay as per the manufacturer’s
(INOVA Diagnostics, San Diego, CA)
product insert. These assays have been
approved by the food and drug admin-
istration for in vitro diagnostic use
in gluten-sensitive enteropathy. The
cutoff values (o20 Units¼negative;
all assays) recommended by the manu-
facturer were used for statistical analy-
sis. Sensitivity, specificity, positive
and negative predictive values, and
the area under the receiver operating
characteristic curve were calculated
for each assay. Ninety-five percent
confidence intervals were also com-
puted for sensitivity, specificity, and
positive and negative predictive values.
All statistics were generated using
SAS software, version 9.1 of the SAS
system for Windows (SAS institute Inc.,
Cary, NC).
While identifying patients with DH
on a normal diet, IgA anti-eTG per-
formed better than any other single
marker associated with gluten-sensitive
enteropathy (Table 1). The sensitivity of
IgA anti-eTG was lower (60.0%) in our
cohort of prospective DH patients,
which is likely attributed to their gluten
restriction and/or treatment. When con-
sidering both retrospective and pro-
spective DH patients, there were 28
(21.5%) with IgA anti-eTGþ /IgA anti-
tTG results, but only 1 (0.8%) having
IgA anti-eTG/IgA anti-tTGþ results. A
negative result for IgA anti-tTG in a
patient suspected of having DH, how-
ever, does not rule out the diagnosis.
These results show that about 20% of
DH patients will be negative for IgA
anti-tTG Abs, but positive for IgA anti-
eTG, and only rare patients are positive
for IgA anti-tTG and negative for IgA
anti-eTG.
We did not have enough clinical
information on patients in the prospec-
tive DH cohort to correlate levels of IgA
anti-eTG with disease parameters
Table 1. Statistical comparison between IgA anti-epidermal transglutaminase (eTG) and other markers for gluten-
sensitive enteropathy in 80 retrospective sera from patients with dermatitis herpetiformis and 49 sera from normal
adults
eTG IgA tTG IgA tTG IgG DGP IgA DGP IgG
% Sensitivity (95% CI) 71.3 (60.1–80.8) 48.8 (37.4–60.2) 2.5 (0.3–8.7) 61.3 (49.7–71.9) 46.3 (35.0–57.8)
% Specificity (95% CI) 100 (92.8–100) 100 (92.8–100) 100 (92.8–100) 93.9 (83.1–98.7) 100 (92.8–100)
% PPV (95% CI) 100 (93.7–100) 100 (91.0–100) 100 (15.8–100) 94.2 (84.1–98.8) 100 (90.5–100)
% NPV (95% CI) 68.1 (56.0–78.6) 54.4 (43.6–65.0) 38.6 (30.1–47.6) 59.7 (47.9–70.8) 53.3 (42.6–63.7)
AUC 0.912 0.778 0.709 0.845 0.825
AUC, area under curve; CI, confidence interval; DGP, deamidated gliadin peptides; NPV, negative predictive value; PPV, positive predictive value; tTG,
tissue transglutaminase.
Table 2. Serology results for serial blood draws from a single DH patient on a strict gluten-free diet
eTG IgA tTG IgA tTG IgG DGP IgA DGP IgG
Pre Dx 76 209 1 210 90
60 days post Dx 14 58 2 44 75
12 months post Dx 2 12 1 7 6
DGP, deamidated gliadin peptides; DH, dermatitis herpetiformis; Dx, diagnosis; eTG, epidermal transglutaminase; tTG, tissue transglutaminase.
12 Units or greater for IgA anti-eTG=positive; 20 Units or greater IgA and IgG anti-tTG and DGP=positive.
The patient did not take dapsone.
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(degree and duration of gluten restric-
tion or dapsone/sulfapyridine dose);
however, future studies should attempt
to correlate levels of IgA anti-eTG with
parameters of disease activity, includ-
ing degree and duration of gluten
restriction, and dapsone/sulfapyridine
dose. The patient presented in Table 2
shows that the levels of each Ab assay
decreases over time with adherence to a
gluten-free diet. Although definitive con-
clusions cannot be made from one
patient, these results suggest that the
levels of IgA against eTG correlate with
dietary gluten intake. Prospective studies
should be designed to evaluate the levels
of IgA anti-eTG in DH patients over time
after initiation of a gluten-free diet.
IgA anti-eTG was present in only
11.1% of pediatric CD, which is
significantly lower than that reported
in adult CD (B50%) (Hull et al., 2008).
These results are similar to our pre-
viously published data showing a low
prevalence of IgA anti-eTG in pediatric
CD patients. This occurred in the
setting of significantly elevated concen-
trations of IgA anti-tTG (90.7%). The
majority of the six pediatric CD patients
with IgA anti-eTGþ results showed low
titers (13, 13, 14, 15, 20, and 96 Units)
and all were duodenal biopsy positive
(1 of 18 Marsh 3a (5.6%), 1 of 15 Marsh
3b (6.7%), and 4 of 16 Marsh 3c
(25.0%)). All six pediatric CD patients
were also positive for IgA anti-tTG (6 of
6), for IgA anti-deamidated gliadin
peptides (6 of 6), and for IgG anti-
deamidated gliadin peptides (5 of 6).
We will follow-up pediatric CD
patients with IgA anti-eTGþ results to
find out whether they develop symp-
toms of DH.
In conclusion, IgA anti-eTG was
more sensitive in detecting DH
than any other marker associated with
gluten-sensitive enteropathy and its
prevalence is significantly lower in
pediatric CD than that which has
been reported in adult CD. In a
patient suspected of having DH, the
present data support testing for IgA
anti-eTG, which may help in screening
and monitoring the response to a
gluten-free diet. We then recommend
a biopsy of uninvolved, perilesional
skin in an area of grouped vesicles or
erosions for direct immunofluores-
cence, which is the gold standard for
diagnosis.
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
We thank Gold Standard Diagnostics (Davis, CA)
for donating the IgA anti-eTG kits and INOVA
Diagnostics (San Diego, CA) for donating the IgA
and IgG anti-tTG and deamidated gliadin peptide
kits for this study. This study was supported by
NIH grant DK50678 to John J Zone, by the
Dermatology Foundation to Christopher M Hull,
by a VA merit award to Laurence J Meyer and by
the Associated Regional and University Patholo-
gists (ARUP) Institute for Clinical and Experimen-
tal Pathology.
Troy D. Jaskowski1, Tracy Hamblin2,
Andrew R. Wilson1, Harry R. Hill1,3,4,5,
Linda S. Book6, Laurence J. Meyer2,7,
John J. Zone2 and
Christopher M. Hull2
1Associated Regional and University
Pathologists (ARUP) Institute for Clinical and
Experimental Pathology, Salt Lake City, Utah,
USA; 2Department of Dermatology, University
of Utah School of Medicine, Salt Lake City,
Utah, USA; 3Department of Pathology,
University of Utah School of Medicine, Salt
Lake City, Utah, USA; 4Department of
Pediatrics, University of Utah School of
Medicine, Salt Lake City, Utah, USA;
5Department of Medicine, University of Utah
School of Medicine, Salt Lake City, Utah, USA;
6Department of Pediatric Gastroenterology,
University of Utah School of Medicine, Salt
Lake City, Utah, USA and 7Salt Lake City
Department of Veterans Affairs, Salt Lake City,
Utah, USA
E-mail: jaskowtd@aruplab.com
REFERENCES
Donaldson MR, Zone JJ, Schmidt LA, Taylor TB,
Neuhausen SL, Hull CM et al. (2007)
Epidermal transglutaminase deposits in peri-
lesional and uninvolved skin in patients with
dermatitis herpetiformis. J Invest Dermatol
127:1268–71
Hull CM, Liddle M, Hansen N, Meyer LJ, Schmidt
L, Taylor T et al. (2008) Elevation of IgA anti-
epidermal transglutaminase antibodies in
dermatitis herpetiformis. Br J Dermatol
159:120–4
Sardy M, Karpati S, Merkl B, Paulsson M,
Smyth N (2002) Epidermal transglutaminase
(TGase 3) is the autoantigen of
dermatitis herpetiformis. J Exp Med 195:
747–57
The Absence of BRAF, FGFR3, and PIK3CA Mutations
Differentiates Lentigo Simplex from Melanocytic Nevus
and Solar Lentigo
Journal of Investigative Dermatology (2009) 129, 2730–2735; doi:10.1038/jid.2009.146; published online 18 June 2009
TO THE EDITOR
Lentigo simplex (LS) is a benign skin
lesion preferentially observed in young-
er people, although it may occur at any
age. The lesion measures a few milli-
meters in diameter, is brown to black,
and is clinically indistinguishable from
a melanocytic nevus. Histopathologi-
cally, LS shows a moderate elongation
of the epidermal rete ridges and basal
hyperpigmentation. The number of
melanocytes in the basal epidermal
layer may be slightly increased. In
contrast to LS, solar lentigo displays
markedly elongated rete ridges and
profound actinic elastosis in the dermis.
It has been proposed that LS mayAbbreviations: LS, lentigo simplex
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